Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre
|
|
- Wilfrid Spencer Page
- 5 years ago
- Views:
Transcription
1 532304TAR / Therapeutic Advances in Respiratory DiseaseR Condliffe, CA Elliot research-article2014 Therapeutic Advances in Respiratory Disease Original Research Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre Robin Condliffe, Charlie A. Elliot, Judith Hurdman, Ian Sabroe, Catherine Billings, David G. Kiely and Neil Hamilton Ther Adv Respir Dis 2014, Vol. 8(3) DOI: / The Author(s), Reprints and permissions: journalspermissions.nav Abstract Introduction: Ambrisentan is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial hypertension (PAH). There are few data on clinical use and long-term tolerability in a wider range of patients with pulmonary hypertension (PH). Methods: All patients treated with ambrisentan over a 4-year period were identified. Baseline characteristics, liver function test (LFT) results and World Health Organization (WHO) functional class were retrieved from hospital databases. Results: 272 patients received ambrisentan between March 2009 and June 2013 (32% idiopathic PAH, 36% connective tissue disease PAH, 11% congenital heart disease PAH, 6% portopulmonary hypertension, 1% HIV PAH, 4% PH in association with lung disease, 8% chronic thromboembolic PH and 2% PH in association with sarcoidosis). 33.5% of patients received ambrisentan as monotherapy and 12% received ambrisentan as their initial PH therapy. 18% stopped treatment due to side effects and 12% stopped due to lack of efficacy. Oedema was the most common side effect leading to cessation of therapy, which occurred in 7% of patients. 57% of patients who discontinued ambrisentan due to side effects also discontinued other PAH therapies due to side effects previously or subsequently. Ambrisentan was discontinued in two (<1%) patients due to abnormal LFTs. The 3-year survival in congenital heart disease PAH, idiopathic PAH and systemic sclerosis-associated PAH was 80%, 62%, and 38%, respectively (p = 0.003). Survival was superior in patients in whom WHO functional class improved in response to therapy. Conclusion: Ambrisentan is used as an initial therapy and as monotherapy in a minority of patients in a large UK PH referral centre. Discontinuation due to side effects, and especially oedema, was higher than reported in previous studies while discontinuation due to abnormal LFTs was very uncommon. A majority of patients who discontinued therapy due to side effects also previously or subsequently discontinued other PAH therapies. Improvement in WHO functional class was associated with superior survival. Keywords: ambrisentan, pulmonary hypertension, side effects, liver function tests Introduction Pulmonary arterial hypertension (PAH) is a rare condition characterized by mean arterial pressure 25mmHg in the presence of normal left atrial pressure [Kiely et al. 2013]. It can be idiopathic or heritable in nature, or may be associated with other medical conditions such as connective tissue disease (CTD), congenital heart disease (CHD), liver disease and HIV. It may also occur as a result of exposure to various drugs, most notably anorexigens. Pulmonary hypertension (PH) may also be associated with left heart disease, respiratory disease (PH-Lung) or may occur due to chronic thromboembolic disease (CTEPH) and may also occur in association with other miscellaneous conditions including sarcoidosis [Simonneau et al. 2009]. Current available therapy for PAH includes phosphodiesterase-5 Correspondence to: Robin Condliffe, MD Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield S10 2JF, UK robin.condliffe@sth. nhs.uk Charlie A. Elliot, MBChB Judith Hurdman, MBChB Catherine Billings, PhD David G. Kiely, MD Neil Hamilton, DPhil Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK Ian Sabroe, PhD Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital and Department of Infection and Immunity, University of Sheffield, Sheffield, UK 71
2 Therapeutic Advances in Respiratory Disease 8(3) inhibitors (PDE5-I) sildenafil and tadalafil, endothelin receptor antagonists (ERAs) bosentan and ambrisentan and prostanoids (eposprostenol, iloprost and treprostinil) [Kiely et al. 2013]. Current guidelines do not recommend PAHspecific therapies for patients with PH associated with left heart or lung disease [Galiè et al. 2009]. Endothelin-1 is a potent vasoconstrictor and proproliferative peptide released predominantly in vascular endothelial cells. Endothelin-1 acts via two receptors, ETA and ETB. ETA mediates vasoconstriction and cellular proliferation while ETB promotes vasodilatation and has antiproliferative properties [D Alto, 2012]. Ambrisentan (Volibris, GSK, Brentford, UK; Letairis, Gilead, Foster City, California, USA) is a selective ETA receptor antagonist which was shown to significantly improve exercise capacity, quality of life and time to clinical worsening in two large concurrent randomized, controlled trials of monotherapy, ARIES-1 and ARIES-2 [Galiè et al. 2008]. These studies enrolled patients with idiopathic PAH or PAH associated with anorexigens, CTD and HIV. There are relatively few published data describing the use of ambrisentan in clinical practice and in other forms of PH [Badesch et al. 2012; Judson et al. 2011; Zuckerman et al. 2011]. In the present study we therefore describe tolerability and clinic utility of ambrisentan across the spectrum of PH patients treated in a large PH referral centre over a 4-year period. Methods A total of 272 patients who received ambrisentan between March 2009 and June 2013 were identified from our departmental pharmacy database. Our unit has a referral population of approximately 15 million and >900 patients on PAHspecific therapy. Hospital notes and records were then interrogated to capture demographics, baseline characteristics, concomitant therapies and treatment response. Monthly liver function test (LFT) results for each patient were reviewed. Survival to the census date of 1 July 2013 or date of death was determined via the National Health Service mortality database. Approval for the use of anonymized clinical data had previously been approved by our local research ethics committee. Statistical analysis Descriptive data was presented as mean ± standard deviation or median (interquartile range). Baseline data was compared where appropriate using one-way analysis of variance followed by post hoc Bonferroni corrections. Survival from date of commencement of ambrisentan was assessed using the Kaplan Meier method. Patients who stopped ambrisentan prior to date of death or 1 July 2013 were included in the survival analysis. Results Study population The aetiologies of PH in the 272 patients treated with ambrisentan during the study period were idiopathic/heritable (32%), CTD (36%, 82% of whom had systemic sclerosis), CHD (11%), portopulmonary (6%), HIV (1%), PH-Lung (4%), CTEPH (8%) and sarcoidosis (2%) (Figure 1). A total of 75% of patients were women and the mean age at commencement of therapy was 61.1 ± 16 years. Baseline characteristics of the main groups are described in Table 1. Patients with CHD were the youngest group while CTD patients had the least severely elevated pulmonary pressures and patients with portopulmonary hypertension had the highest cardiac outputs. Of the CHD patients, 16 (55%) had Eisenmenger s syndrome and had not undergone right heart catheterization at our unit, six (21%) had a large defect with significant left to right shunt, four (14%) had a small septal defect and three (10%) had a previously corrected defect. As only 45% of CHD patients underwent right heart catheterization, haemodynamic data is not presented in Table 1. Of the 21 CTEPH patients, 16 (76%) were deemed to have inoperable disease following assessment by the national pulmonary endarterectomy centre while three (14%) had persistent PH following pulmonary endarterectomy and two (10%) had refused surgery despite being operable candidates. Ambrisentan use and discontinuation Median duration of exposure to ambrisentan was 210 (range ) days. The cumulative number of patients prescribed ambrisentan increased exponentially throughout the study period (Figure 2). A total of 91 patients (33.5%) received ambrisentan as monotherapy, 174 patients (65.5%) in combination with a PDE5-I while one patient (0.5%) received combination therapy with intravenous prostanoid and a further single patient (0.5%) also received both a PDE5-I and 72
3 R Condliffe, CA Elliot et al. 272 PH patients treated with ambrisentan Group 1 89 (32%)IPAH 98 (36%) CTD 29 (11%) CHD 16 (6%) Portopulmonary 3 (1%) HIV Group 3 10 (4%) PH-Lung Group 4 21 (8%) CTEPH Group 5 6 (2%) Sarcoid 50 (18%) stopped due to side effects 33 (12%) stopped due to lack of perceived benefit 13 subsequently died 16 subsequently died 3 (1%) stopped due to poor compliance 41 (15%) died while on ambrisentan 145 (54%) receiving ambrisentan at census date 1 July 2013 Figure 1. Patient disposition. Groups 1 5 refer to pulmonary hypertension classification [Kiely et al. 2013]. Abbreviations: IPAH, idiopathic pulmonary arterial hypertension; CTD, connective tissue disease; CHD, congenital heart disease; PH-Lung, pulmonary hypertension in association with lung disease; CTEPH, chronic thromboembolic pulmonary hypertension. intravenous prostanoid. Only 32 patients (12%) commenced ambrisentan de novo. A total of 11 patients (4%) were switched from sitaxentan at its withdrawal from market. A total of 34 patients (13%) switched from bosentan due to abnormal LFTs on that medication while 15 (6%) switched from bosentan and 4 (2%) switched from PDE5-I due to symptomatic side effects. Maximum dosage of ambrisentan was 5 mg daily in 54% and 10 mg daily in 46%. A total of 145 patients (54%) were still receiving ambrisentan on 1 July Of those who were no longer receiving the medication on that date, 41 (15%) had died while still receiving ambrisentan while 50 patients (18%) had stopped treatment due to side effects and 33 (12%) had stopped due to lack of perceived benefit (Figure 1). Three patients (1%) had treatment discontinued due to lack of compliance with LFT monitoring. Oedema was the most common side effect, leading to cessation of therapy in 20 patients (7% of the total patients and 40% of patients stopping therapy due to side effects) (Table 2). Rates of cessation due to oedema were similar in the three main groups of IPAH, systemic sclerosis (SSc) and CHD (5 7%). A total of 29 (57%) of those patients who stopped ambrisentan due to side effects also stopped other PAH therapies previously or subsequently (19 bosentan, three sildenafil, six both bosentan and sildenafil and one prostanoid therapy). Median duration of therapy prior to stopping due to side effects was 43 (range ) days with 74% of those patients stopping within the first 100 days. The form of PH in the 50 patients who stopped therapy due to side effects was idiopathic PAH 73
4 Therapeutic Advances in Respiratory Disease 8(3) Table 1. Baseline characteristics at diagnosis of the whole cohort and main subgroups. PH IPAH SSc CHD Porto Lung CTEPH Sarcoid N Age, years 61 ± ± ± 12 #+ 48 ± 16 * 63 ± ± ± 14 #+ 60 ± 9 WHO II/III/IV, % 5/78/17 6/80/15 4/72/24 4/92/4 14/86/0 0/44/56 0/90/10 0/60/40 mrap, mmhg 11 ± 6 12 ± 6 9 ± 6 10 ± 6 13 ± 6 14 ± 6 14 ± 7 mpap, mmhg 51 ± ± ± 12 # 51 ± ± ± ± 5 PAWP, mmhg 12 ± 4 12 ± 3 10 ± 4 13 ± 5 12 ± 5 12 ± 5 11 ± 3 CI, L/min/m ± ± ± ± 0.4 # 2.7 ± ± ± 0.8 PVR, dyn/s/cm ± ± ± 354 # 432 ± 230 # 730 ± ± ± 262 No haemodynamics displayed for CHD as minority of group underwent right heart catheterization. Abbreviations: PH, pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; SSc, systemic sclerosis associated PAH; CHD, congenital heart disease associated PAH; Porto, portopulmonary hypertension; Lung, lung disease associated PH; CTEPH, chronic thromboembolic PH; Sarcoid, sarcoidosis associated PAH; WHO, World Health Organization; mrap, mean right atrial pressure; mpap, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; CI, cardiac index; PVR, pulmonary vascular resistance; # p < 0.05 compared with IPAH; p < 0.05 compared with SSc; + p < 0.05 compared with CHD; compared with portopulmonary; * p < 0.05 compared with PH-Resp; p < 0.05 compared with CTEPH; ± p < 0.05 compared with Sarcoid. Data is presented as mean ± standard deviation Patients initiated on ambrisentan Mar-09 Jun-09 Sep-09 Dec-09 Mar-10 Jun-10 Sep-10 Dec-10 (12; 24%), CTD (14; 28%), CHD (8; 16%), portopulmonary (1; 2%), PH-Lung (4; 8%), CTEPH (10; 20%) and sarcoidosis (1; 2%). There was no significant difference in gender or age between those patients who stopped therapy due to side effects or continued therapy. Patients who discontinued due to therapy did however have significantly higher mean right atrial pressure (13.7 ± 6 mmhg versus 10.9 ± 6 mmhg; p = 0.005) and pulmonary artery wedge pressure (13.1 ± 4 mmhg versus 11.1 ± 4 mmhg; p = 0.009) compared with patients who continued therapy. Out of the 10 patients with PH-Lung, four patients stopped therapy due to side effects and one due to lack of perceived benefit. Out of the 21 patients with CTEPH, 10 patients stopped due to side effects and two due to lack of perceived benefit. Only one out of six patients with sarcoidosis stopped therapy due to side effects. Mar-11 Jun-11 Date Figure 2. Cumulative number of patients initiated on ambrisentan during the study period. Sep-11 Dec-11 Mar-12 Jun-12 Sep-12 Dec-12 Mar-13 Jun-13 Two patients stopped due to abnormal LFTs. The first patient had previously stopped bosentan due to abnormal transaminases which had normalized on withdrawal of bosentan. This patient developed elevated transaminases >7 upper limit of normal (ULN) 16 months after commencing ambrisentan with no elevation in bilirubin. LFTs normalized on cessation of ambrisentan. The patient did have a history of severe eczema occasionally requiring flucloxacillin for superimposed infection but it was not clear whether flucloxacillin was being taken at the time of the transaminase abnormality. The patient has subsequently represented, despite not receiving an endothelin receptor antagonist, with elevated transaminases of unknown origin. A second patient developed transaminases >3 ULN, with normal bilirubin, following 9 months of ambrisentan. LFTs normalized on cessation and the abnormality recurred on rechallenging with ambrisentan with subsequent normalization on further cessation. No patients switching from sitaxentan developed abnormal LFTs. Survival and response to therapy Overall median survival from commencement of ambrisentan was 3.2 years. The 3-year survival in the three largest patient groups was CHD 80%, IPAH 62% and SSc-PAH 38% (p = 0.003, Figure 3). There was no significant difference in survival between those patients who continued ambrisentan or stopped due to lack of clinical benefit or side effects. Survival from commencement of ambrisentan was superior in those patients who improved 74
5 R Condliffe, CA Elliot et al. Table 2. Predominant side effect leading to cessation of ambrisentan therapy. Side effect Number (% of total patients exposed) Oedema 20 (7) Nausea 7 (3) Myalgia 3 (1) LFT abnormality 2 (1) Dyspnoea 4 (1.5) Headache 1 (0.5) Hair loss 1 (0.5) Dizziness 2 (1) Anaemia 1 (0.5) Rash 3 (1) Unclear 6 (2) LFT, liver function test. Improved Stable Worsened Figure 4. Survival by change in World Health Organization (WHO) functional class following commencement of ambrisentan treatment. Figure 3. Survival from commencing ambrisentan in the three main patient groups. their World Health Organization (WHO) functional class at 3 6 months following commencement of ambrisentan (p = 0.03, Figure 4). Follow-up exercise capacity at 3 6 months following commencement of ambrisentan was only located for 54% of patients making meaningful conclusions regarding effects on exercise capacity impossible. Discussion The current study reports clinical use and tolerability of ambrisentan in a general population of PH patients. The efficacy of ambrisentan as monotherapy in PAH (predominantly idiopathic PAH and CTD-PAH) over a 12-week period was demonstrated, in the ARIES-1 and ARIES-2 randomized, controlled studies [Galiè et al. 2008]. The ARIES-E extension study demonstrated persistent benefit in exercise capacity after up to 2 years of treatment with 82% of patients remaining on ambrisentan monotherapy [Oudiz et al. 2009]. Peripheral oedema was the most commonly reported side effect occurring in between 10 30% of patients and being reported as severe in only 1.3% of patients in the extension study. No LFT abnormalities in patients receiving ambrisentan in ARIES-1 and ARIES-2 were observed while the annual risk of transaminase levels > 3 ULN in ARIES-E was 2% with two out of 383 patients discontinuing ambrisentan as a result of LFT abnormalities. There are relatively few data describing the long-term use of ambrisentan in a less strictly defined population more reflective of the real world. The observational ARIES-3 study enrolled 224 patients across several PH classifications (69 idiopathic PAH, 40 CTD, 10 CHD, 13 drugs/toxins, 45 PH-Lung and 29 CTEPH) [Badesch et al. 2012]. Approximately 50% of patients were receiving concomitant PAH therapy at commencement of ambrisentan. Over a 24-week period significant improvements in 6 Minute Walk 75
6 Therapeutic Advances in Respiratory Disease 8(3) Distance (6MWD) and B-Type Natriuretic peptide (BNP) were observed in the majority of PH groups. Ambrisentan was generally well tolerated with discontinuation due to peripheral oedema occurring in 2.7% and only two episodes of abnormal LFTs. A small observational study followed 27 PAH patients over a longer period of time (52 weeks) and observed improvements in 6MWD, pro-nt BNP and pulmonary haemodynamics [D Alto et al. 2012] Further post hoc and subgroup analysis of patients enrolled in ARIES-1 has been published [Blalock et al. 2010; Klinger et al. 2011] while there are limited data suggesting benefits in patients with portopulmonary hypertension [Cartin-Ceba et al. 2011] and Eisenmenger s syndrome [Zuckerman et al. 2011]. The incidence of LFT abnormalities in a post-marketing surveillance study enrolling almost 11,000 patients in the USA (LEAP programme) reported possible hepatic events in 2.87% of patients with only 79 (0.72%) being deemed clinically significant events and only six cases having elevations in both transaminases and bilirubin [Ben-Yehuda et al. 2012]. In the current paper, only one-third of patients received ambrisentan as monotherapy and 88% of patients had previously been treated with other PAH therapies, most commonly PDE5-I. This reflects commissioning and prescribing practice in the UK whereby initial therapy for PAH is PDE5-I with subsequent addition or switch to other therapies if initial response is suboptimal. We observed a low rate of discontinuation due to abnormal LFTs despite regular monitoring but discontinuation due to peripheral oedema was 2 3 times greater than that seen in ARIES-E [Oudiz et al. 2009]. The proportion of patients stopping therapy due to any side effects was 18.5% which was approximately three times greater than that observed in ARIES-E. There are several possible reasons for the higher discontinuation rate we observed. As the majority of patients were not treatment-naïve, the greater incidence of peripheral oedema may reflect more advanced disease with worsened right ventricular function. A post hoc analysis of ARIES-1 and 2 data demonstrated, however, that oedema occurred even when BNP fell and 6MWD increased suggesting that, in patients enrolled in ARIES-1 and 2 at least, peripheral oedema did not reflect worsened right heart failure [Shapiro et al. 2012]. It was interesting to observe that 57% of patients stopping treatment in the current study also stopped other PAH therapies due to side effects. This may reflect a lower symptom threshold in clinical practice or an increased difficulty in withdrawing medication in patients enrolled in clinical trials. Survival from commencement of ambrisentan in the current study was inferior to that observed in ARIES-E where overall 2-year survival was 88% [Oudiz et al. 2009]. It is well recognized that survival in patients enrolled in randomized controlled trials is superior to that observed in registries due to the more stable disease state of study patients. Survival in patients with CHD was superior to that of patients with idiopathic PAH which in turn was superior to that seen in SSc-PAH. These differences in survival have previously been described elsewhere [Hurdman et al. 2012] and likely reflect differences in cardiac contractility and pulmonary vasculopathy between the groups [Dimopoulos et al. 2008; Overbeek et al. 2008, 2009]. Survival in patients continuing ambrisentan or stopping therapy due to side effects or lack of clinical benefit was not significantly different, however, due to the heterogeneous patient group and uncontrolled nature of this study it is not possible to infer a lack of efficacy based on these data. Although the data did not allow demonstration of response to therapies in terms of exercise capacity, patients with improvements in WHO functional class did have superior survival to patients who did not improve functional class. Limitations This data was derived in a single centre. Patients were managed and monitored as clinically required meaning a standardized therapeutic approach and follow-up data at set intervals was not present for all patients, limiting conclusions regarding possible efficacy. Conclusions Clinical use of ambrisentan differs from that seen in the original randomized controlled trials. The majority of patients treated with ambrisentan in a UK PH referral centre did not receive it as firstline therapy or as monotherapy and other forms of PH not studied in ARIES-1 and 2 were also treated with ambrisentan. LFT abnormalities were infrequent, although drug cessation due to side effects including peripheral oedema was more common than in the published literature to date. Patients who improved functional class in response to therapy had superior survival compared with those who did not improve FC. 76
7 R Condliffe, CA Elliot et al. Funding This research received no specific grant from any funding agency in the public, commercial, or notfor-profit sectors. Conflict of interest statement RC, CAE, DGK and NDH have received honoraria from GSK pharmaceuticals for lecturing, conference travel and advisory boards. References Badesch, D., Feldman, J., Keogh, A., Mathier, M., Oudiz, R., Shapiro, S. et al. (2012) Aries-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 30: Ben-Yehuda, O., Pizzuti, D., Brown, A., Littman, M., Gillies, H., Henig, N. et al. (2012) Long-term hepatic safety of Ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol 60: Blalock, S., Matulevicius, S., Mitchell, L., Reimold, S., Warner, J., Peshock, R. et al. (2010) Longterm outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. J Card Fail 16: Cartin-Ceba, R., Swanson, K., Wiesner, R. and Krowka, M. (2011) Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 139: D Alto, M. (2012) An update on the use of ambrisentan in pulmonary arterial hypertension. Ther Adv Respir Dis 6: D alto, M., Romeo, E., Argiento, P., Correra, A., Sarubbi, B., Scognamiglio, G. et al. (2012) Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics. Int J Cardiol 156: Dimopoulos, K., Giannakoulas, G., Wort, S. and Gatzoulis, M. (2008) Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol 23: Galiè, N., Hoeper, M., Humbert, M., Torbicki, A., Vachiery, J., Barbera, J. et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: Galiè, N., Olschewski, H., Oudiz, R., Torres, F., Frost, A., Ghofrani, H. et al. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117: Hurdman, J., Condliffe, R., Elliot, C., Davies, C., Hill, C., Wild, J. et al. (2012) ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 39: Judson, M., Highland, K., Kwon, S., Donohue, J., Aris, R., Craft, N. et al. (2011) Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 28: Kiely, D., Elliot, C., Sabroe, I. and Condliffe, R. (2013) Pulmonary hypertension: diagnosis and management. BMJ 346: f2028. Klinger, J., Oudiz, R., Spence, R., Despain, D. and Dufton, C. (2011) Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension. Am J Cardiol 108: Oudiz, R., Galiè, N., Olschewski, H., Torres, F., Frost, A., Ghofrani, H. et al. (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 54: Overbeek, M., Lankhaar, J., Westerhof, N., Voskuyl, A., Boonstra, A., Bronzwaer, J. et al. (2008) Right ventricular contractility in systemic sclerosisassociated and idiopathic pulmonary arterial hypertension. Eur Respir J 31: Overbeek, M., Vonk, M., Boonstra, A., Voskuyl, A., Vonk-Noordegraaf, A., Smit, E. et al. (2009) Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 34: Shapiro, S., Pollock, D., Gillies, H., Henig, N., Allard, M., Blair, C. et al. (2012) Frequency of edema in patients with pulmonary arterial hypertension receiving ambrisentan. Am J Cardiol 110: Simonneau, G., Robbins, I., Beghetti, M., Channick, R., Delcroix, M., Denton, C. et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54: S43 S54. Zuckerman, W., Leaderer, D., Rowan, C., Mituniewicz, J. and Rosenzweig, E. (2011) Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 107: Visit SAGE journals online SAGE journals 77
Chronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationPrecision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.
1. Eur Respir Rev. 2018 Apr 13;27(148). pii: 180004. doi: 10.1183/16000617.0004-2018. Print 2018 Jun 30. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationIncreasing knowledge about the pathophysiology
Eur Respir Rev 27; 16: 12, 13 18 DOI: 1.1183/95918.124 CopyrightßERSJ Ltd 27 Dual endothelin receptor antagonism: setting standards in PAH M. Humbert ABSTRACT: Endothelin (ET) has emerged as a key mediator
More informationComparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry
nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationTherapeutic Advances in Respiratory Disease. Original Research
573373TAR0010.1177/1753465815573373Therapeutic Advances in Respiratory DiseaseC Howard, K Rangajhavala research-article2015 Therapeutic Advances in Respiratory Disease Original Research Pulmonary artery
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationTreatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost
Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost Xinpeng Han MD, Yuhai Zhang PhD, Liang Dong MD, Liying Fang MD, Yaqin Chai MD, Mengjie Niu MD, Yongping
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationSelection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort
Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort Robert Schilz, DO, PhD, FCCP Medical Director, Lung Transplantation and Pulmonary Vascular Disease
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationClinical Commissioning Policy: Selexipag in the treatment of Pulmonary Arterial Hypertension
Clinical Commissioning Policy: Selexipag in the treatment of Pulmonary Arterial Hypertension Reference: NHS England: 16017/P NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationEffect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis
To cite: Monfredi O, Heward E, Griffiths L, et al. Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis. Open
More information2012 CADTH Symposium. April 2012
2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationPulmonary arterial hypertension (PAH) is
Eur Respir Rev 21; 19: 118, 314 32 DOI: 1.1183/95918.781 CopyrightßERS 21 REVIEW Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationAdvanced Therapies for Pharmacological Treatment of Pulmonary Hypertension
Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationLong-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 54, No. 21, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.07.033
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationAddition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy
Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy Wouter Jacobs, MD, a Anco Boonstra, MD, PhD, a J. Tim Marcus, PhD, b Pieter E. Postmus, MD, PhD, a and Anton Vonk-Noordegraaf,
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION Macitentan (Opsumit Actelion Pharmaceuticals Canada Inc.) Indication: Pulmonary Arterial Hypertension Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that
More informationLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationPulmonary hypertension; does gender matter?
Pulmonary hypertension; does gender matter? Nazzareno Galiè Istituto di Cardiologia Università di Bologna nazzareno.galie@unibo.it Galiè N et al. European Heart Journal (2009) 30, 2493 2537 Pulmonary Hypertension
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationAmbrisentan Therapy for Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 3, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.04.050
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationTITLE: Combination Therapy for Pulmonary Arterial Hypertension: A Review of the Clinical Effectiveness
TITLE: Combination Therapy for Pulmonary Arterial Hypertension: A Review of the Clinical Effectiveness DATE: 01 December 2011 CONTEXT AND POLICY ISSUES Pulmonary arterial hypertension (PAH) is a chronic
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationClinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension
Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension Reference: NHS England A11X04/01 Information Reader Box (IRB) to be inserted on inside front cover
More informationOverview of current therapeutic approaches for pulmonary hypertension
Review Article Overview of current therapeutic approaches for pulmonary hypertension Jason A. Stamm 1, Michael G. Risbano 2, and Michael A. Mathier 3 1 Department of Pulmonary, Allergy, and Critical Care
More informationPulmonary arterial hypertension (PAH) Predicting survival in pulmonary arterial hypertension in the UK
Eur Respir J 2012; 40: 604 611 DOI: 10.1183/09031936.00196611 CopyrightßERS 2012 Predicting survival in pulmonary arterial hypertension in the UK Wai-Ting Nicola Lee*, Yi Ling*, Karen K. Sheares #, Joanna
More informationSafety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension
CHEST Original Research PULMONARY VASCULAR DISEASE Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension Rodrigo Cartin-Ceba, MD ; Karen Swanson, DO ; Vivek Iyer, MD ; Russell
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 15, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationClinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension
[ Original Research Pulmonary Vascular Disease ] Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension Mark-Jan Ploegstra, MD ; Sanne Arjaans, BSc ; Willemijn M.
More informationRisk Stratification in Pulmonary Hypertension and Pregnancy
Risk Stratification in Pulmonary Hypertension and Pregnancy Dr Robin Condliffe Pulmonary Vascular Disease Unit Royal Hallamshire Hospital Sheffield United Kingdom Conflicts of Interest Honorararia Actelion,
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationMedical Therapy for Chronic Thromboembolic Pulmonary Hypertension
Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension Josanna Rodriguez-Lopez, MD Pulmonary Hypertension and Thromboendarterectomy Program Massachusetts General Hospital Harvard Medical School
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationSurvival in patients with pulmonary arterial hypertension treated with first-line bosentan
European Journal of Clinical Investigation (2006) 36 (Suppl. 3), 10 15 Blackwell Publishing Ltd Survival in patients with pulmonary arterial hypertension treated with first-line bosentan V. V. McLaughlin
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More informationPulmonary arterial hypertension (PAH) is a. The use of combination therapy in pulmonary arterial hypertension: new developments REVIEW
Eur Respir Rev 2009; 18: 113, 148 153 DOI: 10.1183/09059180.00003809 CopyrightßERSJ Ltd 2009 REVIEW The use of combination therapy in pulmonary arterial hypertension: new developments N. Galiè*, L. Negro*
More informationPulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies
Pulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies Nick H. Kim, M.D. Clinical Professor of Medicine Director, Pulmonary Vascular Medicine Clinical Service Chief, PCCSM La Jolla Pulmonary,
More informationThe need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension
REVIEW 6MWD IN PAH TRIALS The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension Sean Gaine 1 and Gérald Simonneau 2 Affiliations: 1 National Pulmonary Hypertension
More informationClinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages)
Clinical Commissioning Policy: Selexipag for treating pulmonary arterial hypertension (all ages) NHS England Reference: 170065P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationClinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
Research Article Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension Roxana Sulica 1, Swathi Sangli 2, Aloke Chakravarti 3
More informationPulmonary arterial hypertension (PAH) is a
Eur Respir J 2007; 30: 1103 1110 DOI: 10.1183/09031936.00042107 CopyrightßERS Journals Ltd 2007 A USA-based registry for pulmonary arterial hypertension: 1982 2006 T. Thenappan, S.J. Shah, S. Rich and
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More informationOptimal management of severe pulmonary arterial hypertension
Eur Respir Rev 2011; 20: 122, 254 261 DOI: 10.1183/09059180.00007011 CopyrightßERS 2011 REVIEW Optimal management of severe pulmonary arterial hypertension O. Sitbon and G. Simonneau ABSTRACT: Over the
More informationSelexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension
Eur Respir J 2012; 40: 874 880 DOI: 10.1183/09031936.00137511 CopyrightßERS 2012 : an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension Gérald Simonneau*,
More informationPrior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationDoes Tadalafil Improve Exercise Capacitance in Patients over 12 Years Old with Pulmonary Hypertension?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Does Tadalafil Improve Exercise Capacitance
More informationAdvanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension. Original Policy Date
MP 5.01.07 Advanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationDue to their very nature, orphan diseases. Results of European post-marketing surveillance of bosentan in pulmonary hypertension
Eur Respir J 2007; 30: 338 344 DOI: 10.1183/09031936.00138706 CopyrightßERS Journals Ltd 2007 Results of European post-marketing surveillance of bosentan in pulmonary hypertension M. Humbert*, E.S. Segal
More informationFunctional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry
CHEST Original Research PULMONARY VASCULAR DISEASE Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry Robyn J. Barst, MD ;
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information